The cell transformation assay to assess potential carcinogenic properties of nanoparticles
Authors: Hayrapetyan, R., Lacour, T., Luce, A., Finot, F., Chagnon, M.C. and Séverin, I.
Journal: Mutation Research - Reviews in Mutation Research
Volume: 791
eISSN: 1388-2139
ISSN: 1383-5742
DOI: 10.1016/j.mrrev.2023.108455
Abstract:Nanoparticles (NPs) are present in many daily life products with particular physical-chemical properties (size, density, porosity, geometry …) giving very interesting technological properties. Their use is continuously growing and NPs represent a new challenge in terms of risk assessment, consumers being multi-exposed. Toxic effects have already been identified such as oxidative stress, genotoxicity, inflammatory effects, and immune reactions, some of which are leading to carcinogenesis. Cancer is a complex phenomenon implying multiple modes of action and key events, and prevention strategies in cancer include a proper assessment of the properties of NPs. Therefore, introduction of new agents like NPs into the market creates fresh regulatory challenges for an adequate safety evaluation and requires new tools. The Cell Transformation Assay (CTA) is an in vitro test able of highlighting key events of characteristic phases in the cancer process, initiation and promotion. This review presents the development of this test and its use with NPs. The article underlines also the critical issues to address for assessing NPs carcinogenic properties and approaches for improving its relevance.
Source: Scopus
The cell transformation assay to assess potential carcinogenic properties of nanoparticles.
Authors: Hayrapetyan, R., Lacour, T., Luce, A., Finot, F., Chagnon, M.-C. and Séverin, I.
Journal: Mutat Res Rev Mutat Res
Volume: 791
Pages: 108455
eISSN: 1388-2139
DOI: 10.1016/j.mrrev.2023.108455
Abstract:Nanoparticles (NPs) are present in many daily life products with particular physical-chemical properties (size, density, porosity, geometry …) giving very interesting technological properties. Their use is continuously growing and NPs represent a new challenge in terms of risk assessment, consumers being multi-exposed. Toxic effects have already been identified such as oxidative stress, genotoxicity, inflammatory effects, and immune reactions, some of which are leading to carcinogenesis. Cancer is a complex phenomenon implying multiple modes of action and key events, and prevention strategies in cancer include a proper assessment of the properties of NPs. Therefore, introduction of new agents like NPs into the market creates fresh regulatory challenges for an adequate safety evaluation and requires new tools. The Cell Transformation Assay (CTA) is an in vitro test able of highlighting key events of characteristic phases in the cancer process, initiation and promotion. This review presents the development of this test and its use with NPs. The article underlines also the critical issues to address for assessing NPs carcinogenic properties and approaches for improving its relevance.
Source: PubMed
The cell transformation assay to assess potential carcinogenic properties of nanoparticles.
Authors: Hayrapetyan, R., Lacour, T., Luce, A., Finot, F., Chagnon, M.-C. and Séverin, I.
Journal: Mutation research. Reviews in mutation research
Volume: 791
Pages: 108455
eISSN: 1388-2139
ISSN: 1383-5742
DOI: 10.1016/j.mrrev.2023.108455
Abstract:Nanoparticles (NPs) are present in many daily life products with particular physical-chemical properties (size, density, porosity, geometry …) giving very interesting technological properties. Their use is continuously growing and NPs represent a new challenge in terms of risk assessment, consumers being multi-exposed. Toxic effects have already been identified such as oxidative stress, genotoxicity, inflammatory effects, and immune reactions, some of which are leading to carcinogenesis. Cancer is a complex phenomenon implying multiple modes of action and key events, and prevention strategies in cancer include a proper assessment of the properties of NPs. Therefore, introduction of new agents like NPs into the market creates fresh regulatory challenges for an adequate safety evaluation and requires new tools. The Cell Transformation Assay (CTA) is an in vitro test able of highlighting key events of characteristic phases in the cancer process, initiation and promotion. This review presents the development of this test and its use with NPs. The article underlines also the critical issues to address for assessing NPs carcinogenic properties and approaches for improving its relevance.
Source: Europe PubMed Central